Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 6Esophageal Neoplasms 4Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Adenocarcinoma 2Solid Tumor 1Rectal Neoplasms 1Pathologic Complete Response 1Neoplasms, Unknown Primary 1Nasopharyngeal Carcinoma 1Locally Advanced Gastric Adenocarcinoma 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × tegafur-gimeracil-oteracil × Clear all
NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡